Bowman and Brooke Logo

INSIGHTS

Bowman and Brooke lawyers speak regularly at legal education conferences and industry associations. They write for professional and industry publications, providing thought leadership on legal topics and industry trends.
October 19, 2015

FDA vs. First Amendment: The Future of the FDA's Broad Prohibition on Off-Label Promotion After Amarin

news icon

Austin Partner Susan Burnett authored an article for the DRI Drug and Medical Device Committee's newsletter, RX for the Defense. In "FDA vs. the First Amendment: The Future of the FDA's Broad Prohibition on Off-Label Promotion After Amarin," she dissects a New York federal court's ruling in Amarin Pharma, Inc. v. United States Food & Drug Administration, which upholds drugmakers' rights to truthfully promote their products' unapproved uses.

Related: